A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone
NCT02652650 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2016-06-06
Summary
The purpose of this study is to evaluate the effect of steady-state concentrations of JNJ-63623872 on the steady-state pharmacokinetics of ethinylestradiol and norethindrone in healthy female participants.
Conditions
- Healthy
Interventions
- DRUG
-
Ethinylestradiol
Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
- DRUG
-
Norethindrone
Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
- DRUG
-
JNJ-63623872
Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
Sponsors & Collaborators
-
Janssen Research & Development, LLC
lead INDUSTRY
Principal Investigators
-
Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC
Study Design
- Allocation
- NA
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-12-31
- Primary Completion
- 2016-06-30
- Completion
- 2016-06-30
Countries
- Belgium
Study Locations
More Related Trials
-
Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol
NCT02170038 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Efficacy and Safety With the Transdermal Contraceptive System.
NCT00236769 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females
NCT03126097 ·Status: TERMINATED ·Phase: PHASE1
-
The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects
NCT02832180 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)
NCT01650168 ·Status: COMPLETED
-
A Pharmacokinetic Study of Colchicine With an Oral Contraceptive
NCT01040845 ·Status: COMPLETED ·Phase: PHASE1
-
TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.
NCT00739622 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age
NCT06354257 ·Status: COMPLETED ·Phase: PHASE1
-
Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.
NCT05505162 ·Status: COMPLETED ·Phase: PHASE1
-
Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive
NCT00196326 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers
NCT01246791 ·Status: COMPLETED ·Phase: PHASE3
-
CP-690,550 And Oral Contraception Drug-Drug Interaction Study
NCT01137708 ·Status: COMPLETED ·Phase: PHASE1
-
A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors
NCT02705963 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants
NCT04718636 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women
NCT00915668 ·Status: WITHDRAWN ·Phase: PHASE1
-
An Open-label Study to Evaluate Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of Norelgestromine and Ethinyl Estradiol
NCT00307632 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
NCT00236795 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids
NCT04018274 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
NCT06657105 ·Status: COMPLETED ·Phase: PHASE1
-
Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive Steroids
NCT04267250 ·Status: COMPLETED ·Phase: PHASE1
-
Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate
NCT05294341 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive
NCT07215806 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Safety and Efficacy of an Oral Contraceptive
NCT00477633 ·Status: COMPLETED ·Phase: PHASE3
-
The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females
NCT00254800 ·Status: COMPLETED ·Phase: PHASE1
-
Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions
NCT01340625 ·Status: COMPLETED ·Phase: PHASE1